PsyMed Ventures Research
Investment Thesis
PsyMed Ventures is a specialist venture firm focused on the future of brain and mental health. The URL supplied for this task, https://psymed.vc, currently resolves to a domain-sale page rather than an operating investor website, so the operating first-party site used for research is https://psymed.ventures. PsyMed states that it funds and supports founders elevating brain and mental health through innovative neuroscience and frontier technologies, and that PsyMed founders should align healing, responsibility, and profitability. That language is important because it frames the firm as both mission-driven and commercially oriented: PsyMed is looking for companies where clinical impact, patient safety, regulatory credibility, and venture-scale markets can coexist.
The firm is best understood as a frontier brain and mental health investor rather than a broad healthcare generalist. Its first-party investment focus includes artificial intelligence, neurotech and human augmentation, precision neuroscience, new modalities such as genetic, RNA, and cell interventions, holistic medicine, neurometabolism, platforms and novel therapeutics, and digital health and therapeutics. This creates a wide aperture across therapeutics, devices, AI, care delivery, and software, but only when the company has a direct connection to brain health, mental illness, neuropsychiatry, neurological disease, or mental healthcare delivery.
PsyMed's public writing on psychedelic biotech gives additional texture to its underwriting style. Matias Serebrinsky and Greg Kubin have written that psychedelic medicine, digital therapeutics, precision psychiatry, and neurotechnology can change how mental health is treated, while also emphasizing team quality, defensible and ethical IP, clinical development, and the ability to responsibly bring powerful mental health medicines to patients. A practical anti-thesis follows from that: weakly evidenced consumer wellness, generic healthcare software without a brain or mental health wedge, unfocused biotech platforms, questionable psychedelic IP strategies, and teams lacking scientific, clinical, or regulatory credibility are poor fits.
Stage Focus
PsyMed appears most active from pre-seed through Series A, with the clearest activity at pre-seed and seed. Source-backed investments include Aerska's 2025 seed financing, Jimini Health's 2024 pre-seed launch, Neurode's 2024 pre-seed financing, Remepy's 2024 seed round, Freedom Biosciences' 2022 seed round, and Journey Clinical's 2023 Series A. The first-party portfolio also includes companies that reached IPO, acquisition, or strategic combination, including atai Life Sciences, Beckley Psytech, Bright Minds Biosciences, and Gilgamesh Pharmaceuticals. Those later outcomes appear to be portfolio milestones rather than evidence that PsyMed is primarily a late-stage investor.
Check Size
PsyMed does not publish a formal check-size policy on its first-party site. Psychiatry Tech reported a $25 million fund in 2022 for early-stage mental health, psychedelics, neurotechnology, digital health, and precision psychology startups. Because the firm has also operated with syndicate-style activity, check size likely varies by allocation and round construction. A conservative matching range is $200,000 to $1,000,000, with flexibility for smaller syndicate allocations or larger aggregate exposure across rounds. This range should be treated as an estimate rather than a first-party stated target.
Lead Tendency
The source-backed pattern suggests PsyMed is usually a specialist participant or co-investor rather than the default institutional lead. Aerska's seed financing was co-led by Age1, Backed VC, and Speedinvest, with PsyMed participating. Jimini Health's pre-seed included Zetta Venture Partners, LionBird, PsyMed, BoxGroup, Arkitekt Ventures, SCB, and others. Neurode's pre-seed was led by Khosla Ventures with PsyMed participation. Remepy's seed was led by NFX, with PsyMed among the participating investors. Journey Clinical's Series A was led by Union Square Ventures, with PsyMed participating. For matching, PsyMed should be modeled as follows or co-invests, with high value from domain expertise and specialist network support.
Recent Activity
The most recent source-backed investment activity found is Aerska's October 2025 launch with $21 million in seed financing to develop RNAi medicines for brain diseases. PsyMed participated alongside Blueyard, Lingotto, Norrsken VC, Kerna, Ada Ventures, and co-leads Age1, Backed VC, and Speedinvest. In 2024, PsyMed participated in Jimini Health's $8 million pre-seed round for clinician-led, AI-supported therapy; Neurode's $3.5 million pre-seed financing for a wearable ADHD neurostimulation device; and Remepy's $10 million seed financing for hybrid drugs combining traditional therapeutics with digital therapeutic interventions. Portfolio outcome activity also shows the category maturing: atai and Beckley Psytech announced a strategic combination in June 2025, and AbbVie completed its acquisition of Gilgamesh Pharmaceuticals' bretisilocin program in October 2025.
Portfolio Highlights
PsyMed's first-party portfolio is substantial for a specialized fund. It includes biotech and therapeutics companies such as Aerska, atai Life Sciences, Beckley Psytech, Bexson Biomedical, Bloom Science, Bright Minds Biosciences, Delix Therapeutics, Freedom Biosciences, Gilgamesh Pharmaceuticals, Iris Medicine, Mindstate Design Labs, Reset Pharma, Sculpta Bio, Tactogen, Terran Biosciences, and multiple stealth biotech efforts. Neurotechnology and device exposure includes Motif Neurotech, Neurode, Sanmai, and stealth neurotech companies. Digital health and care delivery exposure includes Jimini Health, Journey Clinical, Maya Health, Remepy, Humans Anonymous, TRIPP, and related mental-health infrastructure. The portfolio pattern is coherent: PsyMed backs both regulated therapeutics and software or device companies when the product directly improves brain or mental health outcomes.
Team
PsyMed's listed team includes Matias Serebrinsky, General Partner and Co-Founder; Greg Kubin, General Partner and Co-Founder; Danny Carbonero, PhD, Investment Associate; Martina Galdos, Operations Lead; Tucker Schwartz, Analyst; and Dina Burkitbayeva, MBA/MS, Co-Founder. The firm's venture partner and advisor network appears central to diligence. Tim Gardner, PhD is listed as a venture partner and University of Oregon bioengineering chair with prior Neuralink involvement. Negin Mohktari, PhD is listed as a venture partner with biotech investment experience. John Krystal, MD is an advisor with Yale psychiatry and neuroscience leadership. Graham Pechenik, JD advises on legal and IP. Jacob Robinson, PhD advises on neurotechnology and is CEO and Co-Founder of Motif Neurotech. Chrystal Mavros, PhD and Alex Amen, PhD add expertise across microbiology, gene therapy, gut-brain biology, sequencing, brain analysis, and gene and cell therapies.
Decision Process
PsyMed does not publish a formal investment committee process or decision timeline. The most defensible model is a partnership-led process involving the general partners, with specialized review from venture partners, advisors, and clinical or scientific experts depending on the company. For therapeutics and neurotechnology, likely diligence areas include mechanism, data quality, preclinical or clinical development path, IP, safety, ethics, capital intensity, regulatory path, and downstream financing risk. For digital health and care delivery, likely diligence areas include clinical workflow, patient outcomes, responsible AI behavior, reimbursement or buyer durability, provider adoption, and regulatory boundaries. A one-month timeline is a conservative estimate for a diligence-heavy specialist fund.
Founder Preferences
PsyMed is likely most receptive to founders with deep founder-market fit in neuroscience, psychiatry, biotech, neurotechnology, responsible AI, care delivery, or mental health infrastructure. Strong fits include scientific founders with credible CNS or drug-development experience, technical founders building AI systems that improve diagnosis or care quality, clinicians creating scalable care models, and device founders with a plausible path through clinical validation and regulatory approval. The firm appears to value responsibility in commercialization, especially for psychedelic medicine and other high-impact mental health interventions. Founders should be prepared to explain not only market size and product velocity, but also why the intervention is safe, clinically meaningful, ethically defensible, and fundable through future milestones.
Geographic Focus
PsyMed is associated with San Francisco, California, and its portfolio shows geographic flexibility. Source-backed investments include companies in the United States, Ireland, Israel, Australia, and other startup or science hubs. For routing, the safest geography preferences are US and North America first, with openness to Europe, the UK, Israel, Australia, and MENA when the company squarely fits the brain health, mental health, neurotechnology, or biotech thesis.
Source Notes
Primary sources used include PsyMed's active first-party site at https://psymed.ventures, the supplied https://psymed.vc domain read, Psychiatry Tech coverage of PsyMed's $25 million fund, TechCrunch writing by PsyMed partners on evaluating psychedelic biotech companies, and source-backed announcements for Aerska, Jimini Health, Neurode, Remepy, Journey Clinical, Freedom Biosciences, atai/Beckley, and AbbVie/Gilgamesh.